HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MICOT PHARMA-B

24.100

-1.940-7.45%

Volume:725.60K

Turnover:18.34M

Market Cap:7.99B

PE:- -

High:26.500

Open:26.060

Low:23.840

Close:26.040

52wk High:45.040

52wk Low:23.840

Shares:331.74M

HK Float Shares:280.07M

Volume Ratio:1.09

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:-33.17%

PB:7.24

PE(LYR):- -

PS:23355.77

Loading ...

Overview Company News Filings

Micot Pharma Reports Stable Share Base for July 2026, Confirms Public Float Compliance

Bulletin Express

Hong Kong Stock Movers: MICOT PHARMA-B Surges Over 3% After Phase II Trial for Acute Ischemic Stroke Meets Primary Endpoint

Micot Pharma Gets Topline Results from AIS Drug Candidate Study; Shares Jump 3%

MT Newswires Live

Shaanxi Micot Pharmaceutical Technology Co Says Phase II Trial of Mt200605 for AIS Reaches Primary Endpoint

Shaanxi Micot Pharmaceutical Technology Co - Phase Ii Trial of Mt200605 for Ais Reaches Primary Endpoint with Statistically Significant Outcomes

THOMSON REUTERS

MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)

Shaanxi Micot Says Phase II Trial Database Lock Completed for Stroke Drug Candidate Mt200605

Shaanxi Micot Pharma Enrolls First Patient in Anticoagulation Drug Trial

MT Newswires Live

Micot Pharma initiates Phase II trial of dual-functional antithrombotic MT1002 with first hemodialysis patient enrolled

Bulletin Express

Shaanxi Micot Enrolls First Patient in Phase II Trial of Mt1002 Anticoagulant in Hemodialysis Patients

MICOT PHARMA-B Shares Gain Over 3% Following Milestone in Stroke Drug Trial

Shaanxi Micot Pharma Enrolls First Patient in Acute Ischemic Stroke Drug Trial

MT Newswires Live

Micot Pharma Enrolls First Patient in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke

Bulletin Express

MICOT PHARMA-B (02335) Announces First Patient Dosed in Phase Ib/II Trial for Acute Ischemic Stroke Treatment MT1002

Shaanxi Micot Enrolls First Patient in Phase Ib/ii Mt1002 Acute Ischemic Stroke Trial

How MICOT PHARMA-B Secured Short-Term Inclusion in the Southbound Stock Connect Despite Differences Among 18A Companies

Movement Alert｜Micot Pharma-B Falls 5.03% in Regular Trading, Profit-Taking Continues on Fifth Trading Day Post-IPO

Movement Alert｜Micot Pharmaceutical-B Falls 7.89% in Regular Trading, Profit-Taking Continues on Fourth Trading Day After IPO

Movement Alert｜Micot Pharmaceutical-B Falls 6.28% in Regular Trading, Profit-Taking Emerges on Third Day After IPO Surge

Hong Kong Stocks Rebound; Seer Intelligent Technology, Micot Pharma Shine on Debut

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/02335/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02335","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02335\",,,,,undefined,":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"MICOT PHARMA-B","latestPrice":24.1,"timestamp":1789027722148,"preClose":26.04,"halted":0,"volume":725600,"delay":0,"changeRate":-0.07450076804915506,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"Closed","change":-1.94,"latestTime":"09-10 16:08:42","open":26.06,"high":26.5,"low":23.84,"amount":18336948,"amplitude":0.102151,"askPrice":24.9,"askSize":400,"bidPrice":24.1,"bidSize":11000,"shortable":0,"etf":0,"ttmEps":-1.265,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":26.04,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":1.09212,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02335\",,,,,undefined,":{"symbol":"02335","floatShares":280071100,"roa":"-33.17%","roe":"--","lyrEps":0,"volumeRatio":1.09212,"shares":331740350,"dividePrice":0,"high":26.5,"amplitude":0.102151,"preClose":26.04,"low":23.84,"week52Low":23.84,"pbRate":"7.24","psRate":"23355.77","week52High":45.04,"institutionHeld":0,"latestPrice":24.1,"committee":0.929825,"eps":0,"divideRate":0,"volume":725600,"delay":0,"ttmEps":-1.265,"open":26.06,"prevYearClose":18.2,"prevWeekClose":28.56,"prevMonthClose":28.5,"prevQuarterClose":36.54,"fiveDayClose":28.54,"twentyDayClose":30.1,"sixtyDayClose":18.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02335\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02335","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02335\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02335\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02335\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02335","date":"2026-09-09","current":-19.051383,"percent":1,"low":-69.768231,"twenty":-61.009443,"median":-47.355727,"eighty":-44.183357,"high":-20.283357,"avg":-48.189554,"sd":13.72329,"marketCap":8638518714},"quantilePoints":[{"date":"2026-06-26","current":-62.263046,"twenty":-62.206329,"median":-60.152258,"eighty":-47.220229,"marketCap":13110378632},{"date":"2026-07-03","current":-59.036408,"twenty":-61.58898,"median":-58.586203,"eighty":-56.979685,"marketCap":12440263125},{"date":"2026-07-10","current":-67.90436,"twenty":-64.475349,"median":-60.719674,"eighty":-57.773147,"marketCap":14291374278},{"date":"2026-07-17","current":-63.579874,"twenty":-66.545041,"median":-62.752488,"eighty":-58.496163,"marketCap":13428849368},{"date":"2026-07-24","current":-53.390071,"twenty":-65.175311,"median":-60.719674,"eighty":-54.684103,"marketCap":11279171900},{"date":"2026-07-31","current":-45.013396,"twenty":-64.653423,"median":-59.036408,"eighty":-53.47914,"marketCap":9527582852},{"date":"2026-08-07","current":-44.926163,"twenty":-63.868877,"median":-57.071612,"eighty":-46.373695,"marketCap":9527582852},{"date":"2026-08-14","current":-46.337925,"twenty":-63.512285,"median":-53.986784,"eighty":-46.072055,"marketCap":9839418781},{"date":"2026-08-21","current":-45.768087,"twenty":-63.046152,"median":-53.612744,"eighty":-46.072055,"marketCap":9739896676},{"date":"2026-08-28","current":-44.884949,"twenty":-62.24414,"median":-48.311254,"eighty":-45.062515,"marketCap":9554122080},{"date":"2026-09-04","current":-22.281867,"twenty":-61.878748,"median":-47.732514,"eighty":-44.372782,"marketCap":9474504396},{"date":"2026-09-09","current":-20.283357,"twenty":-61.009443,"median":-47.355727,"eighty":-44.183357,"marketCap":8638518714}],"updateTime":1789048896844},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02335\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1164063868","title":"Micot Pharma Reports Stable Share Base for July 2026, Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164063868","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164063868?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:10","pubTimestamp":1785834631,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) filed its monthly return for the period ended 31 July 2026, indicating no changes to either its registered or issued share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102821392","title":"Hong Kong Stock Movers: MICOT PHARMA-B Surges Over 3% After Phase II Trial for Acute Ischemic Stroke Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1102821392","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102821392?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:44","pubTimestamp":1785825858,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) shares rose more than 3% in Hong Kong trading, climbing 3.4% to HK$30.40 as of the time of writing, with turnover reaching HK$20.4952 million.The company announced on August 3...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","PSYK","VXUS","02335","BK4588","BMED","KCAI","IBBJ","BK4585","BK1161","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656587054","title":"Micot Pharma Gets Topline Results from AIS Drug Candidate Study; Shares Jump 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656587054","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656587054?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:27","pubTimestamp":1785824827,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology's  phase II clinical trial of MT200605 for the treatment of AIS obtained top-line results, according to a Monday Hong Kong bourse filing.Shares of the company were nearly 3% in Tuesday afternoon trading.Results showed that the study reached its primary endpoint with statistically significant and clinically meaningful outcomes, with the drug showing a favorable efficacy trend and safety and tolerability profile.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656370053","title":"Shaanxi Micot Pharmaceutical Technology Co Says Phase II Trial of Mt200605 for AIS Reaches Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2656370053","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656370053?lang=en_us&edition=fundamental","pubTime":"2026-08-03 23:33","pubTimestamp":1785771237,"startTime":"0","endTime":"0","summary":"BRIEF-Shaanxi Micot Pharmaceutical Technology Co Says Phase II Trial Of MT200605 For AIS Reaches Primary EndpointAug 3 -Shaanxi Micot Pharmaceutical Technology Co Ltd2335.HK:PHASE II TRIAL OF MT200605 FOR AIS REACHES PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT OUTCOMESFurther company coverage:2335.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44011U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656370837","title":"Shaanxi Micot Pharmaceutical Technology Co - Phase Ii Trial of Mt200605 for Ais Reaches Primary Endpoint with Statistically Significant Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2656370837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656370837?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:53","pubTimestamp":1785768838,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44011U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142184840","title":"MICOT PHARMA-B (02335) Completes Data Lock for Phase II Clinical Trial of MT200605 in Acute Ischemic Stroke (AIS)","url":"https://stock-news.laohu8.com/highlight/detail?id=1142184840","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142184840?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:48","pubTimestamp":1784893701,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (02335) has announced that the Phase II clinical trial for its candidate drug MT200605, designed to treat acute ischemic stroke, has successfully completed database locking.MT200605 is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","BMED","IBBQ","AIS","BK1161","PSYK","02335","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653814680","title":"Shaanxi Micot Says Phase II Trial Database Lock Completed for Stroke Drug Candidate Mt200605","url":"https://stock-news.laohu8.com/highlight/detail?id=2653814680","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653814680?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:41","pubTimestamp":1784893290,"startTime":"0","endTime":"0","summary":"Shaanxi Micot says Phase II trial database lock completed for stroke drug candidate MT200605Shaanxi Micot Pharmaceutical Technology reported a database lock for its Phase II China trial of MT200605 in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL57gwb9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650291919","title":"Shaanxi Micot Pharma Enrolls First Patient in Anticoagulation Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2650291919","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650291919?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:44","pubTimestamp":1783597458,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology (HKG:2335) enrolled the first patient in a phase II clinical study of its MT1002.The drug is being tested for anticoagulation in HD patients, according to a Thursday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196213061","title":"Micot Pharma initiates Phase II trial of dual-functional antithrombotic MT1002 with first hemodialysis patient enrolled","url":"https://stock-news.laohu8.com/highlight/detail?id=1196213061","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196213061?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:07","pubTimestamp":1783595246,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has officially commenced substantive execution of its Phase II clinical programme for MT1002, following the successful enrolment of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650392513","title":"Shaanxi Micot Enrolls First Patient in Phase II Trial of Mt1002 Anticoagulant in Hemodialysis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2650392513","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650392513?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:44","pubTimestamp":1783593894,"startTime":"0","endTime":"0","summary":"Shaanxi Micot enrolls first patient in Phase II trial of MT1002 anticoagulant in hemodialysis patientsShaanxi Micot Pharmaceutical Technology enrolled the first patient in a China Phase II trial of MT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL8JB3nP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102075450","title":"MICOT PHARMA-B Shares Gain Over 3% Following Milestone in Stroke Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1102075450","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102075450?lang=en_us&edition=fundamental","pubTime":"2026-07-07 11:50","pubTimestamp":1783396221,"startTime":"0","endTime":"0","summary":" Shares of MICOT PHARMA-B (02335) advanced more than 3% in morning trading. At the time of writing, the stock was up 3.53% to HK$39.84, with a turnover of HK$11.28 million. The upward movement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","02335","VXUS","IBBQ","KCAI","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648665379","title":"Shaanxi Micot Pharma Enrolls First Patient in Acute Ischemic Stroke Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648665379","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648665379?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:33","pubTimestamp":1783078403,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology (HKG:2335) enrolled the first patient in a phase Ib/II clinical trial of MT1002.The drug is being tested for the treatment of acute ischemic stroke, according to a Friday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102266225","title":"Micot Pharma Enrolls First Patient in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke","url":"https://stock-news.laohu8.com/highlight/detail?id=1102266225","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102266225?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:24","pubTimestamp":1783077882,"startTime":"0","endTime":"0","summary":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma) has commenced substantive execution of its Phase Ib/II clinical programme for MT1002, an investigational therapy targeting acute...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184437870","title":"MICOT PHARMA-B (02335) Announces First Patient Dosed in Phase Ib/II Trial for Acute Ischemic Stroke Treatment MT1002","url":"https://stock-news.laohu8.com/highlight/detail?id=1184437870","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184437870?lang=en_us&edition=fundamental","pubTime":"2026-07-03 18:36","pubTimestamp":1783074992,"startTime":"0","endTime":"0","summary":"MICOT PHARMA-B (ASX: 02335) has announced that the first patient has been successfully dosed in the Ib/II phase clinical trial for its self-developed investigational drug, MT1002, intended for the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBQ","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648680106","title":"Shaanxi Micot Enrolls First Patient in Phase Ib/ii Mt1002 Acute Ischemic Stroke Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648680106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648680106?lang=en_us&edition=fundamental","pubTime":"2026-07-03 18:30","pubTimestamp":1783074652,"startTime":"0","endTime":"0","summary":"Shaanxi Micot enrolls first patient in Phase Ib/II MT1002 acute ischemic stroke trialShaanxi Micot enrolled the first patient in a Phase Ib/II trial of MT1002 for acute ischemic stroke, moving the stu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nNDL1PwZnZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172693359","title":"How MICOT PHARMA-B Secured Short-Term Inclusion in the Southbound Stock Connect Despite Differences Among 18A Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1172693359","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172693359?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:55","pubTimestamp":1782906912,"startTime":"0","endTime":"0","summary":"Thanks to the short-term and fast-track inclusion mechanism of the Southbound Stock Connect, over ten companies from various sectors have rushed to list in Hong Kong since late June this year, aiming...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","VXUS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189377327","title":"Movement Alert｜Micot Pharma-B Falls 5.03% in Regular Trading, Profit-Taking Continues on Fifth Trading Day Post-IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1189377327","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189377327?lang=en_us&edition=fundamental","pubTime":"2026-06-30 15:51","pubTimestamp":1782805866,"startTime":"0","endTime":"0","summary":"On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.The stock listed on the Hong Kong Stock Exchange on June 24...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180525892","title":"Movement Alert｜Micot Pharmaceutical-B Falls 7.89% in Regular Trading, Profit-Taking Continues on Fourth Trading Day After IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1180525892","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180525892?lang=en_us&edition=fundamental","pubTime":"2026-06-29 09:56","pubTimestamp":1782698167,"startTime":"0","endTime":"0","summary":"On June 29, Micot Pharmaceutical-B declined 7.89% in regular trading, trading at HK$38.52 per share, with turnover of approximately HK$1.97 million.The stock listed on the Hong Kong Stock Exchange on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115013994","title":"Movement Alert｜Micot Pharmaceutical-B Falls 6.28% in Regular Trading, Profit-Taking Emerges on Third Day After IPO Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1115013994","media":"Market Focus","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115013994?lang=en_us&edition=fundamental","pubTime":"2026-06-26 09:33","pubTimestamp":1782437627,"startTime":"0","endTime":"0","summary":"On June 26, Micot Pharmaceutical-B declined 6.28% in regular trading, trading at HK$38.8/share, with turnover of HK$561,600. The stock pulled back from near the HK$40 level reached during the prior...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645958678","title":"Hong Kong Stocks Rebound; Seer Intelligent Technology, Micot Pharma Shine on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2645958678","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645958678?lang=en_us&edition=fundamental","pubTime":"2026-06-24 16:38","pubTimestamp":1782290336,"startTime":"0","endTime":"0","summary":"Hong Kong stocks rebounded Wednesday as investors looked past volatility in AI-related shares and focused on signs of progress in U.S.-Iran peace talks.The Hang Seng Index rose 0.3%, or 75.90 points, to close at 23,412.18, while the Hang Seng China Enterprises Index edged up 5.61 points to finish at 7,764.97.A sharp selloff in semiconductor stocks dragged the Nasdaq and S&P 500 to one-week lows Tuesday amid concerns over AI spending and a more hawkish Fed.Meanwhile, U.S. President Donald Trump said Tuesday that Iran had agreed to allow nuclear inspections indefinitely, a claim Tehran rejected, saying no such concession had been made in ongoing negotiations.The two sides, which concluded a first round of talks in Switzerland on Monday, also offered conflicting accounts on key elements of the framework agreement reached last week.In corporate news, two companies made their trading debut on the Hong Kong bourse.Shanghai Seer Intelligent Technology  closed 4% higher at HK$106.00, compared ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["07500","03037","09115","MCHmain","02833","HSI","HHImain","02335","MHImain","07300","513600","06106","02800","07200","03419","82800","HSTECH","03115","83115"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}